Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty
- 30 June 1992
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 123 (6) , 1439-1444
- https://doi.org/10.1016/0002-8703(92)90792-t
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- A new approach to the treatment of atherosclerosis and trapidil as an antagonist to platelet-derived growth factorPublished by Elsevier ,2002
- Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit.Circulation, 1990
- Reduction in the Rate of Early Restenosis after Coronary Angioplasty by a Diet Supplemented with n–3 Fatty AcidsNew England Journal of Medicine, 1988
- Inhibition of Atherosclerosis by Cod-Liver Oil in a Hyperlipidemic Swine ModelNew England Journal of Medicine, 1986
- The Pathogenesis of Atherosclerosis — An UpdateNew England Journal of Medicine, 1986
- Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model.Circulation Research, 1985
- Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study.Circulation, 1984
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984
- An evidence for “response to injury” hypothesisLife Sciences, 1982